An open-label, multicenter, single dose escalation study evaluating the safety of a single intravitreal injection of three increasing doses of THR-687 found patients who received the highest dose experienced the best gains in vision and reduction of central subfield thickness.
Arshad M. Khanani, MD, presented the results of the phase 1 study at Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2020 symposium in Miami. Study participants received a single intravitreal injection of three increasing doses — 0.4 mg, 1 mg and 2.5 mg — of THR-687 (Oxurion) for
Uncategorized